Source comparison
Comparison: BPC-157 Dosing Across Injury Types and Research Protocols
Achilles Tendon Transection 10 mcg/kg 110–130 mcg Subcutaneous (local) Once daily 14–28 days Lower end of dosing spectrum; local injection critical for efficacy Muscle Crush Injury 10–500 mcg/kg 110–800 mcg Intramuscular Twice daily 7–21 days Higher doses corr
This comparison does not assign a generated winner or score.
- Achilles Tendon Transection
- 10 mcg/kg
- 110–130 mcg
- Subcutaneous (local)
- Once daily
- 14–28 days
- Lower end of dosing spectrum; local injection critical for efficacy
- Muscle Crush Injury
- 10–500 mcg/kg
- 110–800 mcg
- Intramuscular
- Twice daily
- 7–21 days
- Higher doses correlated with faster functional recovery in comparative trials
- Gastric Ulcer Protection
- 10–1000 mcg/kg
- 110–11,000 mcg
- Oral or intraperitoneal
- Once or twice daily
- 7–56 days
- Wide dosing range reflects severity variance; oral shows local GI efficacy but minimal systemic absorption
- Ligament Healing (MCL/ACL)
- Subcutaneous (peri-injury)
- Local injection within 2 cm of injury site required; distant administration ineffective
- Inflammatory Bowel Disease
- Intraperitoneal
- 28–84 days
- Chronic dosing required; divided administration outperformed single bolus in head-to-head trials
- Traumatic Brain Injury
- 7–14 days
- Lowest effective doses in published TBI models; early administration (within 24 hours) appears critical